FATE THERAPEUTICS INC's ticker is FATE and the CUSIP is 31189P102. A total of 240 filers reported holding FATE THERAPEUTICS INC in Q3 2022. The put-call ratio across all filers is 0.68 and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q4 2022 | $3,842,898 | -42.8% | 380,862 | +27.0% | 0.02% | -50.0% |
| Q3 2022 | $6,719,000 | +400.7% | 299,814 | +453.4% | 0.04% | +450.0% |
| Q2 2022 | $1,342,000 | +351.9% | 54,175 | +606.8% | 0.01% | +700.0% |
| Q1 2022 | $297,000 | -95.2% | 7,665 | -89.2% | 0.00% | -96.8% |
| Q2 2021 | $6,178,000 | +16.7% | 71,184 | +10.9% | 0.03% | +6.9% |
| Q1 2021 | $5,292,000 | +77.6% | 64,185 | +95.8% | 0.03% | +61.1% |
| Q4 2020 | $2,980,000 | +934.7% | 32,775 | +355.0% | 0.02% | +800.0% |
| Q3 2020 | $288,000 | +62.7% | 7,204 | -75.1% | 0.00% | +100.0% |
| Q4 2017 | $177,000 | -31.1% | 28,900 | -55.5% | 0.00% | -50.0% |
| Q3 2017 | $257,000 | +24.8% | 65,000 | +2.4% | 0.00% | +100.0% |
| Q2 2017 | $206,000 | +9.6% | 63,500 | +53.8% | 0.00% | 0.0% |
| Q1 2017 | $188,000 | – | 41,300 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| JOHNSON & JOHNSON | 3,379,064 | $7,163,616 | 2.64% |
| Redmile Group, LLC | 13,124,427 | $27,823,785 | 1.32% |
| Monaco Asset Management SAM | 1,847,944 | $3,917,641 | 1.16% |
| Casdin Capital, LLC | 2,050,000 | $4,346,000 | 0.48% |
| TANG CAPITAL MANAGEMENT LLC | 700,000 | $1,484,000 | 0.21% |
| GCM Grosvenor Holdings, LLC | 495,916 | $1,051,342 | 0.21% |
| Nebula Research & Development LLC | 163,617 | $346,868 | 0.18% |
| Bellevue Group AG | 4,851,579 | $10,285,347 | 0.17% |
| Bruce & Co., Inc. | 200,000 | $424,000 | 0.14% |
| XTX Topco Ltd | 192,920 | $408,990 | 0.07% |